Table 1.

Clinical and Molecular Features of Colon Cancer According to FASN Overexpression

Clinical or Molecular Feature	All Cases		FASN Negative		FASN Positive		P
	No.	%	No.	%	No.	%
Total No.	647		563		84
Sex							.68
Male, HPFS	287	44	248	44	39	46
Female, NHS	360	56	315	56	45	54
Age, years							.37
Mean	66.6		66.7		65.7
SD	8.3		8.0		10.0
Prediagnosis BMI, kg/m2							.002
Mean	26.5		26.6		25.2
SD	4.7		4.8		3.7
BMI, kg/m2							.04
< 25	262	42	219	40	43	52
25-27.5	155	25	132	24	23	28
27.5-30	98	16	89	16	9	11
≥ 30	108	17	101	19	7	8.5
Year of diagnosis							.77
Before 1990	100	15	86	15	14	17
1990 to 1999	471	73	409	73	62	74
2000 to 2002	76	12	68	12	8	9.5
Tumor location*							.17
Proximal	371	58	317	57	54	65
Distal	268	42	239	43	29	35
Tumor stage							.01
I	135	21	118	21	17	20
II	222	34	181	32	41	49
III	162	25	143	25	19	23
IV	82	13	79	14	3	3.6
Unknown	46	7.1	42	7.5	4	4.8
Tumor grade							.78
Low	573	89	499	89	74	88
High	71	11	61	11	10	12
MSI							0.01
Low/MSS	514	81	455	83	59	71
High	119	19	95	17	24	29
CIMP							.39
Low/0	523	81	458	81	65	77
High	124	19	105	19	19	23
KRAS mutation							.70
Negative	403	63	352	64	51	61
Positive	233	37	201	36	32	39
BRAF mutation							.73
Negative	520	84	451	84	69	85
Positive	100	16	88	16	12	15
p53 expression							.83
Negative	393	61	342	61	51	62
Positive	250	39	219	39	31	38

Abbreviations: FASN, fatty acid synthase; HPFS, Health Professionals Follow-Up Study; NHS, Nurses’ Health Study; SD, standard deviation; BMI, body mass index; MSI, microsatellite instability; MSS, microsatellite stable; CIMP, CpG island methylator phenotype.

^*Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to sigmoid colon.